SCHEDULE: Armistice Capital Discloses 5.86% Stake in Autolus Therapeutics

Armistice Capital, LLC and Steven Boyd have reported a passive beneficial ownership of 5.86% in Autolus Therapeutics plc, holding 15.6 million American Depositary Shares.

Summary

• Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, disclosing their beneficial ownership in Autolus Therapeutics plc.
• The reporting persons collectively beneficially own 15,600,000 American Depositary Shares (ADS).
• This ownership represents 5.86% of Autolus Therapeutics plc's outstanding class of securities.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Armistice Capital, LLC, as the investment manager, exercises voting and investment power over the securities held by Armistice Capital Master Fund Ltd., the direct holder.
• Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these securities.
• The percentage is based on 266,141,411 shares outstanding as of August 11, 2025, as reported in the Issuer's 10-Q filed on August 12, 2025.

Sentiment

Score: 7

Explanation: The disclosure of a significant 5.86% passive stake by a reputable investment firm like Armistice Capital is generally viewed positively by the market, as it suggests institutional confidence in Autolus Therapeutics' future prospects.

Positives

• A significant institutional investor, Armistice Capital, has taken a notable 5.86% stake in Autolus Therapeutics, potentially signaling confidence in the company's long-term prospects.
• The investment is stated to be for the ordinary course of business, indicating a passive, long-term investment strategy rather than an activist one.

Future Outlook

This filing does not contain future outlook statements.

Industry Context

The disclosure of a significant stake by an investment firm like Armistice Capital in a biotechnology company such as Autolus Therapeutics can be viewed within the broader context of institutional interest in the healthcare and biopharmaceutical sectors. Such investments often reflect a belief in the potential of the company's pipeline or market position, especially in a capital-intensive industry like biotech.

Comparison to Industry Standards

• Armistice Capital's 5.86% stake in Autolus Therapeutics is a substantial position for an institutional investor, indicating a high conviction in the company. For comparison, similar significant stakes by hedge funds or investment managers in other clinical-stage biotech companies often range from 5% to 15%, depending on the company's market capitalization and stage of development.
• The filing of a Schedule 13G, rather than a 13D, signifies a passive investment intent, which is a common approach for many institutional investors who seek long-term capital appreciation without engaging in activist campaigns. This aligns with standard practices for funds that primarily focus on portfolio management.

Stakeholder Impact

• Shareholders: Existing shareholders may view the entry of a significant institutional investor positively, potentially leading to increased market confidence and share price stability.
• Management: Management may see this as a vote of confidence in their strategy and operations.

Key Dates

Recommendation

This filing is a disclosure of a passive ownership stake by an institutional investor. While the entry of a significant investor like Armistice Capital can be a positive signal, it does not provide new fundamental information about Autolus Therapeutics' operational performance, financial health, or strategic direction. Therefore, without additional information, a 'hold' recommendation is appropriate, as the filing itself doesn't warrant a change in investment thesis but rather confirms institutional interest.

Keywords

Autolus Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, ADS, American Depositary Shares, Institutional Investor, Biotechnology, Healthcare Investment